Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Clin Infect Dis. 2011 Oct;53(8):817-25. doi: 10.1093/cid/cir494.

PMID:
21921225
2.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

3.

Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.

Dorrucci M, Rezza G, Porter K, Phillips A; Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration.

J Infect Dis. 2007 Feb 15;195(4):525-34. Epub 2007 Jan 10.

PMID:
17230412
4.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration).

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):158-65.

PMID:
11588510
5.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR.

Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Review.

6.

Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.

Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M; CASCADE Collaboration.

AIDS. 2011 May 15;25(8):1041-9. doi: 10.1097/QAD.0b013e3283463ec5.

PMID:
21412128
7.

Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.

Clements M, Law M, Pedersen C, Kaldor J; CASCADE Collaboration.

HIV Med. 2003 Oct;4(4):332-7.

8.
9.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31.

10.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration.

HIV Med. 2000 Oct;1(4):224-31.

11.
12.

Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.

Clin Infect Dis. 2013 Mar;56(6):888-97. doi: 10.1093/cid/cis1000. Epub 2012 Dec 7.

PMID:
23223594
13.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

14.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

17.

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

18.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration.

J Natl Cancer Inst. 2010 Jun 2;102(11):784-92. doi: 10.1093/jnci/djq134. Epub 2010 May 4.

19.

Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002.

Dorrucci M, Phillips AN, Longo B, Rezza G; Italian Seroconversion Study.

AIDS. 2005 Feb 18;19(3):331-5.

PMID:
15718844

Supplemental Content

Support Center